* DOMAIN THERAPEUTICS *
2001 - Alsace
Illkirch Graffenstaden
(near Strasbourg)
www.domaintherapeutics.com Discovery, Drugs
Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer
Mission: to discover and develop new treatments notably (but not only) for neurological disorders, with a focus on GPCR-mediated neurotransmitter modulation
Clients: Prescribers (own development up to phase III)
info@domaintherapeutics.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor]
Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly
Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com | Turnover (M€) : n.a.
Total funding (M€) : 29.3
Last funding (M€) : 2.1
Focus : CNS
Position : Clinical
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .12 | 4th round-financing : 2.1 M€ by historical investors (AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners), followed by Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly | RFIND | [7 years] |
| 2008 .12 | Company renamed as Domain Therapeutics (from Faust Pharmaceuticals), with Bernard Gilly as President | ORGF | [7 years] |
| 2008 .01 | Partnering research agreement with Takeda | R&D | [6 years] |
| 2006 .10 | 3rd round-financing : 8.2 M€, by previous shareholders (bridge financing) | RFINC | [5 years] |
| 2006 .02 | Nomination : Thomas Seoh as CEO, taking over from founders | ORGN | [4 years] |
| 2004 .12 | Clinical trial (phase IIa) for FP0011 in ALS and Parkinson's disease (beginning) | CLIN | [3 years] |
| 2004 .04 | 2nd round-financing : 16.0 M€, by La Compagnie Financière Ed. de Rothschild, Siparex, AGF P.E., FCJE, and previous investors | RFINB | [2 years] |
| 2003 .12 | Acquisition of Euroclide, with a target oriented technology platform | ACQ+ | [2 years] |
| 2003 .03 | Company move from Paris to Strasbourg, in the BioValley cluster | ORGL | [1 year] |
| 2002 .02 | 1st round-financing : 3.0 M€, by Sofinnova Partners and Auriga Partners | RFINA | [0 year] |
| 2001 .10 | Company founded as Faust Pharmaceuticals by Maurice Israël, Pierre Potier (Taxotere innovator), Pascal Neuville, based in Paris | ORGF | [0 year] | Actualisation / Updating: 15-Dec-2008 |
|
